Introduction
Vaccines play an indispensible role in the protection against various infectious diseases (virus, bacteria or protozoa) by eliciting antigen-specific T cell and humoral (antibody) responses. Vaccination programs helped to eradicate smallpox and rinderpest diseases and poliomyelitis is in the verge of eradication. Currently, inactivated vaccines (e.g. rabies, influenza, foot and mouth disease), live attenuated vaccines (e.g. poliomyelitis, measles, mumps, rubella, rota, influenza; and infectious bursal disease virus, Newcastle disease virus and infectious bronchitis virus vaccines of birds); and recombinant protein vaccines (e.g. hepatitis B) are licensed for use in humans and animals. In addition, genetically modified vaccines, virus-like particles and DNA vaccines are in various stages of pre-clinical and clinical trials [41] .
Adjuvants play an important role to enhance the magnitude and duration of immunity to vaccines. Live vaccines do not require adjuvants as self-replicating pathogens provide required signals for the activation of immune system. However, inactivated vaccines and recombinant protein vaccines require adjuvants to boost the immunogenicity of vaccine antigens. Currently, irrespective of vaccine candidate, aluminum adjuvants are the only adjuvant licensed for human use worldwide. Other adjuvants such as oil-in-water emulsions, liposomes, toll-like receptor 4 (TLR4) agonists are licensed only for particular vaccine combinations [1, 41] . However, aluminum adjuvants induce only humoral but not cellular immune responses. Also, effective and protective vaccines are not yet available for many of the emerging and re-emerging viral diseases. Therefore, there is an obvious need for the identification of novel molecular adjuvants that induce both cellular and humoral immune responses. This review presents an overview of role of regulatory T cells (Tregs), the immunosuppressors, in the immune response to viruses, and identification and validation of CCR4 as one of the Treg-based adjuvant targets to boost protective immunity to viral diseases and vaccines.
Immune response to vaccines
The ability of a vaccine to confer protection is evaluated on the basis of specificity of immune response, the magnitude and duration of immunity it elicits. In general, the steps and process of mounting immune response to vaccines follow the same pattern as that of infection with pathogens. Thus, cooperation of the members of innate immune compartment such as antigen presenting cells (APC) and NK cells, and adaptive immune compartment (T and B cells) is critical for eliciting protective immune response to vaccines. Cellular immunity plays an important role in the clearance of pathogen-infected cells while antibodies clear cell-free pathogens.
Upon immunization, vaccine antigens are recognized by professional APC such as dendritic cells (DC), macrophages and monocytes. Vaccine antigens express various pathogen-associated molecular patterns and are recognized by diverse pattern-recognition receptors (PRRs) of APC. These PRRs include TLRs, C-type lectin receptors (CLRs such as Dectin-1, Dectin-2, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin or DC-SIGN and mannose receptors), NOD-like receptors (NLRs) and retinoid acid-inducible gene-I (RIG-I)-like receptors (RLRs). While TLRs and CLRs are present both on the surface and endosomes of the APC, NLRs and RLRs are intra-cellular in their location. Signalling by these PRRs activate canonical and non-canonical NF-jB and inflammasome activation resulting in phagocytosis of antigens, secretion of immunomodulatory and inflammatory cytokines, chemokines and production of pathogen-killing molecules. Thus, diversity of PRRs and their location ensure optimal activation of innate immune cells [20, 42] .
The activation and differentiation of antigen-specific T cells require four different signals. The signal 'zero' represents the recognition of pathogens by APC via PRRs that leads to phagocytosis/endocytosis of antigens and activation of APC. The endocytosed external antigens are cleaved into smaller peptides by proteolytic enzymes such as cathepsins. These antigenic peptides are then loaded onto MHC class II molecules and transported to surface of APC for the presentation to CD4
? T cells. The antigenic peptides are recognized by T cell receptor (TCR)-CD3 complex ('signal 1'). The antigens that are produced endogenously because of replication of pathogens within APC, are routed to proteasomes for cleavage and presentation via MHC class I to CD8
? T cells (or cytotoxic T lymphocytes, CTLs). In addition, by a process called 'cross-presentation', DC could also present external antigens in the context of MHC class I molecules to CD8
? T cells.
The activation of APC by pathogens also leads to enhanced surface expression of various co-stimulatory molecules such as CD80, CD86, CD40 and adhesion molecules CD54 and CD58 that provide co-stimulatory signals ('signal 2') to T cells for their activation. In addition, the 'signal 3' in the form of immunomodulatory or polarizing cytokines secreted by APC determines the polarization of CD4
? T cells into distinct subtypes such as Th1, Th2, Th17 or induced Tregs [63, 68] . CD4
? T cells provide help for CD8
? T cells and activated CTLs clear infected cells via cytotoxic programs. CD4
? T cell help is also crucial for B cell activation and antibody production [1] .
Th1 cells express transcription factors T-bet and signal transducer and activator of transcription 4 (STAT4) and produce primarily interferon-c (IFN-c) and interleukin-2 (IL-2). IL-12 produced by APC plays an important role in the differentiation of Th1 cells. Th1 immune responses are primarily cell-mediated and IFN-c secreted by Th1 cells activates macrophages to clear intra-cellular pathogens. Th2 cells express GATA-binding protein 3 and STAT6 and produce IL-4, IL-5 and IL-13. They are important for B cell differentiation and clearance of extra-cellular pathogens and parasites. Th17 cells express retinoic acid-related orphan receptor C (RORC) and STAT3 and produce IL-17A/F, IL-22, IL-21, granulocyte-macrophage colonystimulating factor and chemokine CCL20. IL-21 and ? and constitutively express cytotoxic T-lymphocyte antigen-4 (CTLA-4) and inducible T-cell costimulator [43, 44] (Fig. 1) . FoxP3 governs the functions of Tregs and inflammatory cytokines could render Tregs dysfunctional [6] . Tregs could be 'natural' that are derived from the thymus, or 'induced' or 'adaptive' that are differentiated in the periphery from naïve CD4
? T cells under the influence of APC and TGF-b. As TGF-b is critical cytokine for the expression of both FoxP3 and RORC, the inflammatory cytokines in the microenvironment determine the stability of induced Tregs. Induced Tregs present phenotype similar to that of natural Tregs. However, natural Tregs are neuropilin-1
? and are functionally stable [66] . [16] . Tregs induce catabolism of tryptophan by inducing indoleamine 2,3-dioxygenase in DC via CTLA-4-CD80/CD86 interaction. Tryptophan catabolism leads to the release of kynurenines that are potent immune suppressors [13] . In addition, Tregs also suppress the activation of macrophages, monocytes and B cells [27, 55, 67] .
Regulatory T cell suppress protective immune responses to viruses and vaccines
Tregs are present both in secondary lymphoid tissues and in peripheral tissues such as skin. Tregs are important to prevent tissue damage associated with excessive inflammation following viral infection as indicated by the studies in dengue virus-infected patients and in several experimental models of virus infections including respiratory syncytial virus (RSV) and herpes simplex virus-1 (HSV-1) [14, 24, 28, 61] . However, by their ability to suppress APC, T and B cells, Tregs could also inhibit protective immune responses ? and CD8 ? T cell responses, their proliferation, and effector cell number. Thus Tregs delay the clearance of viruses and enhance their persistence [2, 9, 14, 21-23, 28, 30, 31, 50, 57, 58] .
On the contrary, depletion of Tregs by using anti-CD25 antibody (PC61) before infection with HSV-1, enhanced the HSV-1-specific CTL responses [50] . Also, depletion of memory Tregs or effector Tregs in mice before secondary infection with influenza led to increased magnitude of antigen-specific memory CD8
? T cell responses and airway cytokine and chemokine expression [9] . Similarly, in a neonatal murine model of rotavirus infection, depletion of natural Tregs before virus infection led to augmented CD4 ?
and CD8
? T cell responses to virus, such as proliferation and IFN-c secretion. Interestingly, in the same model, proliferation of CD19
? B cells was also increased [22] . Tregs also diminish immune response to vaccines and in particular by hampering the development of effective immune responses following immunization with poorly immunogenic vaccines. The majority of work on role of Tregs in vaccination was done in diverse tumor models [40] . Immune response to HSV-1 DNA and peptide vaccines and inactivated Japanese encephalitis virus vaccine in mice were compromised by the presence of Tregs [25, 56] , and depletion of Tregs enhanced the CTL response to vaccines and conferred greater protection upon viral challenge [56] .
Enhanced immunogenicity and CD4
? T cell responses upon Treg depletion was also observed in the case of hepatitis B virus recombinant subunit protein vaccine and flu-vaccines (either UV-inactivated influenza PR8/A/34 virus vaccine or specific oligosaccharides scGOS/lcFOS/pAOS of influenza virus) [34, 48, 59] . Analysis of cellular and cytokine profiles from influenza-vaccinated individuals also suggested that Tregs and TGF-b contribute to inhibition of anti-influenza antibody responses following vaccination [64] . Also, tickborne encephalitis or hepatitis B vaccine nonresponder individuals had increased IL-10-producing FoxP3
? Tregs upon vaccination [15] .
Targeting Tregs in vaccination: small molecule CCR4 antagonists as molecular adjuvants Since activation state of DC at the time of encounter with vaccine antigens determines the outcome of the immune responses, limiting the influence of Tregs on DC at this juncture could lead to an enhanced immune response to poor immunogenic vaccine candidates [8] . Although depletion of Tregs by targeting CD25 or the molecules implicated in Treg functions (such as CTLA-4) or inhibition of FoxP3 by using a peptide inhibitor P60, provide proof of principle for targeting Tregs in vaccination, such approaches might not be useful for human. The major reason is that depletion of Tregs or blocking their functions could break immune tolerance and cause autoimmune diseases and inflammatory disorders. The appearance of localized autoimmune disease has been reported in mice as a consequence of Treg depletion [49, 52] . Therefore, any approach that targets Tregs for vaccination purposes should not deplete Tregs and inhibition of their functions should be of transient in nature.
Small molecule antagonist-based approach has been explored to target the interaction between chemokines and their receptors to inhibit transiently the recruitment of Tregs at the site of immunization [7, 12, 38] . Up to 90 % of human Tregs and 15-20 % murine Tregs express CCR4, a chemokine receptor absent on naïve T cells [19] . CCR4 is a receptor for CCL22 and CCL17, the chemotactic agents for Tregs both in vitro and in vivo. Both the chemokines are produced at huge amounts (in nanogram quantities) by DC upon activation and promote the contact between DC and CCR4 ? T cells. Monoclonal antibody to CCL22 significantly blocked the migration of Tregs [11] , thus providing evidence that Tregs could be targeted via chemokine system. Small molecular weight antagonists to CCR4 (Fig. 2) identified by in silico approach blocked the migration of CCR4
? Tregs in vitro and in vivo and enhanced DC- mediated human CD4 ? T cell proliferation in vitro [7, 62] (Fig. 3) . Importantly, use of CCR4 antagonists as 'molecular adjuvants' in vivo in experimental models, amplified cellular and humoral immune responses when injected in combination with mycobacterium, hepatitis B virus or Plasmodium yoelii vaccine antigens [7, 12] . In addition, when combined with anti-tumor vaccines, CCR4 antagonists induced antigen-specific CD8
? T cells and tumor immunity against self-antigens [39] but did not prevent division of Tregs [47] . The CCR4 antagonists did not alter the absolute number of Tregs and compared to longer halflife (about 2-3 weeks) of monoclonal antibodies that were used to deplete Tregs or to inhibit their functions, the halflife of CCR4 antagonists is \24 h. Also, in mice injected with CCR4 antagonists, biological markers of autoimmune disease were not noticed [39] . The significant adjuvant activity observed in diverse models without noticeable side effects provided strong evidence that CCR4 is a sustainable adjuvant target for prophylaxis and therapeutic vaccines. These data also provided a pointer that structural biology, in silico technology and immunology tools could be combined to identify potent molecular adjuvants that might have a wide range utility for vaccines.
Perspective
Although experimental models provided evidence that targeting Tregs would enhance the magnitude and duration of protective immunity to vaccines and pathogens, the translation of these results to clinics is hindered due to the fact that tilting the balance of Tregs would be deleterious. Also, Tregs share most of the surface markers that are common with effector T cells and hence many of the strategies that target Tregs lack specificity. The CCR4 is also expressed by Th2 cells and by a small subset of Th17 cells. Thus, CCR4 antagonists might inhibit antibody responses if used in the context of booster immunization as they might prevent interaction of DC with memory Th2 cells. As naïve T cells and Th1 subsets lack CCR4, the small molecule antagonists to CCR4 could be used to enhance cellular immune responses, which are crucial in viral diseases and in cancers. As DC are highly concentrated at epidermis and dermis, CCR4 antagonists could be used with vaccines for microneedle-based immunization [17] . Further work on pharmacokinetics of CCR4 antagonists, optimum dose-finding study and experiments in non-human primates are necessary before carrying CCR4 antagonists to the clinics and their use as vaccine adjuvant. 
